MyoReGenX™

Incorporating three decades of research in muscle stem cell biology, the MyoReGenX™ platform powers the discovery of small molecules with the potential to treat degenerative muscle diseases.

1 / 4
We are using our MyoReGenX™ platform to generate small molecule drug candidates for diseases and disorders where muscle tissue has been lost or muscle regeneration is defective and where enhanced muscle tissue repair is required.
The MyoReGenX™ platform recreates the muscle stem cell niche, or micro-environment, where muscle progenitor cells reside and divide to maintain, grow, and repair muscle tissue.
The platform explores cell-intrinsic signaling and niche interactions to identify and confirm regenerative defects in muscle diseases and discover small molecules to restore regeneration.
This platform was used to elucidate the defect in muscle regeneration in Duchenne muscular dystrophy and identify small molecules that have directed us to our lead drug candidate.
1 / 4
About Us
Generating Small Molecule Drug
Candidates for Degenerative
Muscle Diseases

We are using our MyoReGenX™ platform to generate small molecule drug candidates for diseases and disorders where muscle tissue has been lost or muscle regeneration is defective and where enhanced muscle tissue repair is required. This could include additional genetic muscular dystrophies as well as indications such as sarcopenia (age-related muscle loss), cachexia associated with cancer or other disease conditions, or muscle loss due to surgery or unforeseen trauma (e.g., combat, accidents, injuries).

A schematic of the MyoReGenX platform